Splenic T cells from healthy control mice showed only marginal T cell proliferation and cytokine production in response to CII stimulation (Figure 8).
Thirty minutes after injection, the majority of resting CD4+ T cells was localized in the T-cell and marginal zone (Fig. 1B).
Moderate elevations (SIRs 2 4) were observed for HL and lymphoplasmacytic, peripheral T-cell, and marginal zone lymphomas, but SIRs for indolent lymphoma subtypes were not elevated.
Indolent subtypes include but are not limited to follicular lymphoma (FL), marginal zone lymphoma (MZL), cutaneous T-cell lymphoma (CTCL), small-cell lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), and lymphoblastic lymphoma, which make up 30% of all NHL cases in the US.
Such effects occurred despite a marginal effect of PARP inhibition on T-cell proliferation.
B-cell lymphomas like follicular lymphoma and marginal zone, as well as certain T-cell lymphomas like mycosis fungoides, often follow a remitting/relapsing course that can include long periods without treatment.
Logistic regression models, adjusted for potential confounders, compared infection-related conditions in controls with HL and NHL patients and by the NHL subtypes diffuse large B-cell, T-cell, follicular and marginal zone lymphoma (MZL).
In addition to overall NHL, we evaluated the main NHL subtypes, including diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, follicular lymphoma (FL) and marginal zone lymphoma (MZL).
Pathologic distributions were as follows: peripheral T-cell lymphoma (PTCL; n = 7), marginal zone B-cell lymphoma (MZBCL; n = 1), lymphoplasmacytic lymphoma (LPL; n = 2), Burkitt's lymphoma (n = 1), other unspecified (T-cell lineage, n = 2; B-cell lineage, n = 2).
